Connect with us

Business

Moderna’s stock surges as new funding sets Phase 3 trial of COVID-19 vaccine candidate to start ‘immediately’ – MarketWatch

Published

on

post featured image
ADVERTISEMENT

Shares of Moderna Inc.
MRNA,
+8.97%
rallied 7.0% in premarket trading Monday, after the biopharmaceutical company announced over the weekend another $472 million commitment from the government to develop a COVID-19 vaccine. SVB Leerink analyst Mani Foroohar said that commitment, which is in addition to the previous commitment of $483 million, will be used to fun the Phase 3 trial of its vaccine candidate, which is “set to begin immediately.” He reiterated his market perform rating and $65 …

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
Philips recalls ventilators, sleep apnea machines due to health risks – Reuters
Article feature image
Bitcoin surges near $40,000 after Elon Musk says Tesla will resume crypto payments when mining is cleaner – Markets Insider
Article feature image
European markets continue march to record highs as Fed meeting looms – CNBC